Antibodies

Anifrolumab (anti-IFNAR1) is a type I interferon (IFN) receptor antagonist, a recombinant monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research.Purity&gt:95%

Application:WB: 1/500 - 1/2000 IHC: 1/200 - 1/1000 ELISA: 1/10000Protein FunctionCalcium/phospholipid-binding protein which promotes membrane fusion and is involved in exocytosis. This protein regulates phospholipase A2

Application:WB: 1/500 - 1/2000 IHC: 1/200 - 1/1000 ELISA: 1/10000Protein FunctionCalcium/phospholipid-binding protein which promotes membrane fusion and is involved in exocytosis. This protein regulates phospholipase A2

Application:WB: 1/500 - 1/2000 IHC: 1/200 - 1/1000 ELISA: 1/10000Protein FunctionCalcium/phospholipid-binding protein which promotes membrane fusion and is involved in exocytosis. This protein regulates phospholipase A2

Application:WB: 1/500 - 1/2000 IHC: 1/200 - 1/1000 ELISA: 1/10000Protein FunctionCalcium/phospholipid-binding protein which promotes membrane fusion and is involved in exocytosis. This protein regulates phospholipase A2

Anrukinzumab (anti-IL-13) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab (anti-IL-13) effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab (anti-IL-13) can be used in studies of ulcerative colitis (UC) as

Anrukinzumab (anti-IL-13) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab (anti-IL-13) effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab (anti-IL-13) can be used in studies of ulcerative colitis (UC) as

Anrukinzumab (anti-IL-13) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab (anti-IL-13) effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab (anti-IL-13) can be used in studies of ulcerative colitis (UC) as

Anrukinzumab (anti-IL-13) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab (anti-IL-13) effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab (anti-IL-13) can be used in studies of ulcerative colitis (UC) as

Antibody Enhancer is a signal enhancing buffer that can be used for the dilution, stabilization and binding capacity enhancement of concentrated antibodies and conjugated antibodies. The product secures molecular conformation and prevents loss of

The anti fluorescence quenching sealing agent is a kind of reagent that can slow down the fluorescence quenching and cure the glass slide to form a permanent hard seal. The cured glass slide does not need to use nail polish or other sealant to seal

anumigilimab.